The Latest Headlines at American Banking and Market News
Tyra Biosciences (NASDAQ:TYRA) Rating Reiterated by HC Wainwright
Tyra Biosciences (NASDAQ:TYRA – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a... More of this article »
Robert W. Baird Increases Thoughtworks (NASDAQ:TWKS) Price Target to $6.00
Thoughtworks (NASDAQ:TWKS – Free Report) had its price objective increased by Robert W. Baird from $5.00 to $6.00 in a report issued on Wednesday morning, Benzinga reports. They currently have an outperform rating on the stock. Several... More of this article »
Upstart (NASDAQ:UPST) PT Lowered to $17.00 at Mizuho
Upstart (NASDAQ:UPST – Free Report) had its price target lowered by Mizuho from $23.00 to $17.00 in a research report report published on Thursday, Benzinga reports. Mizuho currently has an underperform rating on the stock. Other... More of this article »
Upstart (NASDAQ:UPST) Stock Rating Reaffirmed by Needham & Company LLC
Needham & Company LLC reaffirmed their hold rating on shares of Upstart (NASDAQ:UPST – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. UPST has been the topic of several other... More of this article »
Valneva (NASDAQ:VALN) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright restated their buy rating on shares of Valneva (NASDAQ:VALN – Free Report) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $26.00 price objective on the stock. Separately,... More of this article »
Morgan Stanley Lowers Visteon (NASDAQ:VC) Price Target to $135.00
Visteon (NASDAQ:VC – Get Free Report) had its price objective dropped by equities researchers at Morgan Stanley from $145.00 to $135.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently... More of this article »
HC Wainwright Boosts Vericel (NASDAQ:VCEL) Price Target to $55.00
Vericel (NASDAQ:VCEL – Free Report) had its price target upped by HC Wainwright from $53.00 to $55.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a buy rating on the biotechnology... More of this article »
Needham & Company LLC Lowers Vacasa (NASDAQ:VCSA) Price Target to $8.00
Vacasa (NASDAQ:VCSA – Get Free Report) had its price target dropped by research analysts at Needham & Company LLC from $10.00 to $8.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “buy”... More of this article »
Vericel (NASDAQ:VCEL) Stock Rating Lowered by StockNews.com
Vericel (NASDAQ:VCEL – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Friday. A number of other equities research... More of this article »
Viridian Therapeutics (NASDAQ:VRDN) Earns Buy Rating from Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $30.00 target price... More of this article »
TD Cowen Increases Vital Farms (NASDAQ:VITL) Price Target to $37.00
Vital Farms (NASDAQ:VITL – Get Free Report) had its price target lifted by research analysts at TD Cowen from $19.00 to $37.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “hold”... More of this article »
Vera Therapeutics (NASDAQ:VERA) PT Raised to $68.00
Vera Therapeutics (NASDAQ:VERA – Get Free Report) had its price target boosted by equities research analysts at Raymond James from $57.00 to $68.00 in a report released on Friday, Benzinga reports. The firm currently has a “strong-buy”... More of this article »
Needham & Company LLC Raises Veeco Instruments (NASDAQ:VECO) Price Target to $46.00
Veeco Instruments (NASDAQ:VECO – Free Report) had its price target lifted by Needham & Company LLC from $43.00 to $46.00 in a research report released on Wednesday, Benzinga reports. The brokerage currently has a buy rating... More of this article »